day came and went without any word from the jurors in U.S.
District Court in Brooklyn. Juries in lengthy deliberations
often send notes asking to review evidence or legal
instructions, but Shkreli's jury has sent only one note, Tuesday
afternoon, asking for clarification of terms in the case.
They are expected to resume deliberating on Thursday morning.
Before going to trial on securities fraud and conspiracy
charges, Shkreli, 34, was best known for raising the price of
anti-infection drug Daraprim by 5,000 percent in 2015 as chief
executive of Turing Pharmaceuticals.
The criminal case stems from Shkreli's career before Turing,
when he managed hedge funds MSMB Capital and MSMB Healthcare and
drug company Retrophin Inc. Prosecutors have said that between
2009 and 2014, Shkreli lied to MSMB investors, lost their money
and paid them back with stock and cash taken from Retrophin
without the approval of the company's directors.
Shkreli's lawyer, Benjamin Brafman, has argued to jurors that,
while Shkreli may have made statements to investors that were
not entirely accurate, he made them in good faith. He has also
stressed that none of Shkreli's investors lost money, a rarity
in a securities fraud case.
(Reporting by Brendan Pierson; Editing by Jonathan Oatis)
[© 2017 Thomson Reuters. All rights
Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.